Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to 362.87%.

  • Gossamer Bio's EBITDA Margin fell 198700.0% to 362.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 793.2%, marking a year-over-year decrease of 7236400.0%. This contributed to the annual value of 60.63% for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Gossamer Bio's EBITDA Margin stood at 362.87%, which was down 198700.0% from 370.24% recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's EBITDA Margin ranged from a high of 1710.33% in Q3 2022 and a low of 390.85% during Q1 2025
  • For the 4-year period, Gossamer Bio's EBITDA Margin averaged around 619.62%, with its median value being 202.5% (2024).
  • Examining YoY changes over the last 5 years, Gossamer Bio's EBITDA Margin showed a top increase of -198700bps in 2025 and a maximum decrease of -4217200bps in 2025.
  • Gossamer Bio's EBITDA Margin (Quarter) stood at 1612.76% in 2022, then decreased by -13bps to 1400.77% in 2023, then plummeted by -86bps to 202.5% in 2024, then tumbled by -279bps to 362.87% in 2025.
  • Its EBITDA Margin was 362.87% in Q3 2025, compared to 370.24% in Q2 2025 and 390.85% in Q1 2025.